New cholesterol drug VSA003 passes first safety test in healthy volunteers

NCT ID NCT05851066

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase study tested a single dose of VSA003 in 36 healthy Chinese adults to see if it is safe and how the body handles it. The drug aims to help control high cholesterol and triglycerides. Participants received either VSA003 or a placebo, and researchers monitored for side effects and drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

VSA003

What this could lead to

If successful, this could lead to a new treatment option for managing high cholesterol and triglycerides.

What could go wrong

This is an early phase 1 trial in healthy volunteers, so it only tests safety and drug processing, not effectiveness. It may not work in patients or may have side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTRIGLYCERIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dyslipidemias familial hypercholesterolemia hyperlipidemia Hyperlipoproteinemia Type II hypertriglyceridemia inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China